Abstract Vandetanib (ZD6474, Caprelsa, AstraZeneca), an oral small-molecule tyrosine
kinase inhibitor (TKI) that targets the rearranged during transfection receptor (RET), VEGF …

Vandetanib (ZD6474) is an orally bioavailable small molecule tyrosine kinase inhibitor of
multiple growth factor receptors, including RET (Rearrange during transfection), vascular …

Purpose There is no effective therapy for patients with advanced medullary thyroid
carcinoma (MTC). Vandetanib, a once-daily oral inhibitor of RET kinase, vascular …

SUMMARY The US Food and Drug Administration (FDA) approved vandetanib in April 2011
for the treatment of unresectable, locally advanced or metastatic medullary thyroid cancer …

Abstract On April 6, 2011, the US Food and Drug Administration approved vandetanib
(Caprelsa tablets; AstraZeneca Pharmaceuticals LP) for the treatment of symptomatic or …

Vandetanib is an oral tyrosine kinase inhibitor approved for treatment of advanced
symptomatic or progressive medullary thyroid cancer (MTC). The current study …

Medullary thyroid cancer (MTC) is frequently diagnosed in a locally advanced or metastatic
stage, and 10-year survival rates in these cases are below 20%. Cytotoxic chemotherapy …

5503 Background: VAN is a once-daily oral inhibitor of RET, VEGFR, and EGFR signaling.
VAN 300 mg/day has previously shown antitumor activity in a phase II study of patients (pts) …

Vandetanib, an orally active, small-molecule, multi-targeted tyrosine kinase inhibitor,
demonstrates potent inhibitory activity against vascular endothelial growth factor receptor …

Background: A randomized phase III trial demonstrated that vandetanib treatment is effective
in patients with metastatic medullary thyroid cancer (MTC), leading to regulatory approval …